Coloplast A/S (CLPBY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Coloplast A/S (CLPBY) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 48/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Coloplast A/S (CLPBY) Gesundheitswesen & Pipeline-Uebersicht
Coloplast A/S, a Danish multinational, develops and markets specialized medical devices and services within ostomy, continence, wound, and skin care. With a strong global presence, the company distinguishes itself through innovative product design and a focus on improving the quality of life for people with intimate healthcare needs, competing in the medical instruments and supplies sector.
Investmentthese
Coloplast A/S presents a compelling investment case based on its established market position, consistent profitability, and focus on specialized healthcare segments. With a market capitalization of $15.58 billion and a P/E ratio of 25.24, the company demonstrates financial stability. A gross margin of 65.0% and a profit margin of 14.3% indicate efficient operations and strong pricing power. Key value drivers include continued innovation in product development, expansion into emerging markets, and strategic acquisitions. Upcoming catalysts include new product launches in the wound care segment and potential regulatory approvals for urological devices. Potential risks include increasing competition from generic manufacturers and fluctuations in currency exchange rates.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $15.58 billion reflects Coloplast's significant presence in the medical instruments and supplies market.
- P/E ratio of 25.24 indicates investor confidence in Coloplast's earnings potential compared to the industry average.
- Gross margin of 65.0% demonstrates Coloplast's ability to maintain profitability through efficient production and pricing strategies.
- Profit margin of 14.3% highlights Coloplast's effective cost management and operational efficiency.
- Dividend yield of 5.14% offers investors a steady income stream, reflecting the company's commitment to shareholder returns.
Wettbewerber & Vergleichsunternehmen
Staerken
- Strong brand recognition and customer loyalty.
- Diversified product portfolio across multiple healthcare segments.
- Global presence and established distribution network.
- Consistent profitability and strong financial performance.
Schwaechen
- Exposure to currency exchange rate fluctuations.
- Dependence on regulatory approvals for new products.
- Potential for product recalls or liability claims.
- Limited presence in some emerging markets.
Katalysatoren
- Upcoming: Launch of new ostomy care products with enhanced features in Q3 2026.
- Ongoing: Expansion of digital health solutions to improve patient engagement and adherence.
- Ongoing: Strategic partnerships with healthcare providers to expand market reach.
- Upcoming: Regulatory approvals for innovative wound care technologies by end of 2026.
Risiken
- Potential: Increasing competition from generic manufacturers in key product segments.
- Potential: Fluctuations in currency exchange rates impacting revenue and profitability.
- Ongoing: Regulatory changes and pricing pressures affecting reimbursement rates.
- Potential: Product recalls or liability claims related to product safety or efficacy.
- Ongoing: Economic downturns affecting healthcare spending and demand for elective procedures.
Wachstumschancen
- Expansion in Emerging Markets: Coloplast has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions are experiencing rapid growth in healthcare spending and increasing awareness of advanced medical technologies. By tailoring its product offerings to meet the specific needs of these markets and establishing strategic partnerships with local distributors, Coloplast can tap into a large and growing customer base. This expansion could contribute to a 10-15% increase in revenue over the next three to five years.
- New Product Development in Wound Care: Coloplast can drive growth through continued innovation in its wound care segment. The global wound care market is projected to reach $22 billion by 2028, driven by the increasing prevalence of chronic wounds and advancements in wound healing technologies. By developing advanced wound dressings and therapies that address unmet clinical needs, Coloplast can capture a larger share of this market. Focus should be on products that reduce healing time and improve patient outcomes.
- Strategic Acquisitions: Coloplast can pursue strategic acquisitions to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or established market positions in key regions, Coloplast can accelerate its growth and enhance its competitive advantage. Potential acquisition targets include companies specializing in advanced wound care, urological devices, or ostomy care products. These acquisitions can provide access to new markets and technologies, driving long-term growth.
- Digital Health Solutions: Coloplast can leverage digital health technologies to enhance its product offerings and improve patient outcomes. By developing mobile apps and online platforms that provide patients with personalized support and education, Coloplast can improve adherence to treatment plans and enhance patient satisfaction. These digital solutions can also generate valuable data that can be used to improve product development and marketing strategies. The market for digital health solutions is expected to grow significantly in the coming years, presenting a major opportunity for Coloplast.
- Focus on Personalized Healthcare: Coloplast can capitalize on the growing trend towards personalized healthcare by developing products and services that are tailored to the individual needs of patients. This includes using data analytics and artificial intelligence to identify patients who are most likely to benefit from specific treatments and developing customized product solutions. By focusing on personalized healthcare, Coloplast can improve patient outcomes, enhance customer loyalty, and differentiate itself from competitors. This approach aligns with the broader industry trend towards precision medicine and patient-centric care.
Chancen
- Expansion into new geographic markets.
- Development of innovative products and technologies.
- Strategic acquisitions to expand product portfolio.
- Growing demand for specialized healthcare solutions.
Risiken
- Increasing competition from generic manufacturers.
- Pricing pressures from healthcare providers and payers.
- Changes in regulatory requirements.
- Economic downturns affecting healthcare spending.
Wettbewerbsvorteile
- Strong brand reputation and customer loyalty in specialized healthcare segments.
- Extensive product portfolio and innovative product development capabilities.
- Global distribution network and established relationships with healthcare providers.
- Proprietary technologies and patents protecting key products.
- High barriers to entry due to regulatory requirements and specialized knowledge.
Ueber CLPBY
Founded in 1954 in Denmark, Coloplast A/S has evolved into a global leader in intimate healthcare solutions. The company's origins trace back to a nurse's invention of the world's first self-adhesive ostomy bag, a breakthrough that laid the foundation for Coloplast's commitment to innovation and patient-centric care. Today, Coloplast operates in three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care. Its product portfolio includes ostomy care products like SenSura Mio and Brava accessories, continence care solutions such as Conveen Active urine bags and SpeediCath catheters, and wound care products like Biatain Silicone and Comfeel dressings. Additionally, Coloplast offers skin care products and solutions for surgical treatment of urological and gynecological disorders. With a presence in over 40 countries, Coloplast serves a diverse range of healthcare professionals, patients, and caregivers, focusing on improving the quality of life for individuals with intimate healthcare needs. Headquartered in Humlebæk, Denmark, Coloplast continues to invest in research and development to maintain its competitive edge and expand its product offerings.
Was das Unternehmen tut
- Develop and market ostomy care products, including bags and accessories.
- Provide continence care solutions such as catheters and urine bags.
- Offer wound care products, including dressings and skin protectants.
- Develop and market products for surgical treatment of urological and gynecological disorders.
- Provide skin care products including cleansers, moisturizers, and protectants.
- Offer digital solutions to support patients in managing their conditions.
Geschaeftsmodell
- Develops and manufactures medical devices and related products.
- Markets and sells products directly to healthcare providers and patients.
- Distributes products through a network of distributors and retailers.
- Generates revenue through product sales and related services.
Branchenkontext
Coloplast A/S operates within the global medical instruments and supplies industry, a sector characterized by increasing demand driven by an aging population and rising prevalence of chronic diseases. The market is competitive, with key players focusing on innovation, product differentiation, and geographic expansion. The industry is also subject to stringent regulatory requirements and pricing pressures. Coloplast's focus on specialized segments like ostomy care and continence care allows it to maintain a competitive edge through differentiated products and strong brand recognition. The global medical devices market is projected to reach $600 billion by 2026, presenting significant growth opportunities for companies like Coloplast.
Wichtige Kunden
- Hospitals and clinics
- Healthcare professionals (doctors, nurses, etc.)
- Patients with ostomies, incontinence, or wounds
- Retail pharmacies and medical supply stores
Finanzdaten
Chart & Info
Coloplast A/S (CLPBY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Highs On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· 19. Feb. 2020
-
Stocks That Hit 52-Week Highs On Thursday
· 6. Feb. 2020
-
Stocks That Hit 52-Week Highs On Friday
· 17. Jan. 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CLPBY.
Kursziele
Wall-Street-Kurszielanalyse fuer CLPBY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CLPBY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Lars Soren Rasmussen
CEO
Lars Soren Rasmussen is the CEO of Coloplast A/S, leading a global workforce of over 16,000 employees. He has extensive experience in the healthcare industry, with a background in business administration and finance. Prior to joining Coloplast, Rasmussen held leadership positions at various multinational corporations, focusing on strategic planning, operational excellence, and market expansion. His expertise spans across multiple functional areas, including sales, marketing, and research and development.
Erfolgsbilanz: Under Lars Soren Rasmussen's leadership, Coloplast A/S has achieved significant milestones, including the successful launch of several innovative products and the expansion into new geographic markets. He has focused on driving organic growth through product innovation and strategic acquisitions. Rasmussen has also overseen initiatives to improve operational efficiency and enhance customer satisfaction, contributing to the company's consistent profitability and strong financial performance.
Coloplast A/S ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. For Coloplast A/S (CLPBY), each ADR represents a specific number of the company's ordinary shares traded on its home market. ADRs allow U.S. investors to invest in foreign companies without the complexities of cross-border transactions, providing easier access and liquidity.
- Heimatmarkt-Ticker: Copenhagen Stock Exchange (Nasdaq Copenhagen), Denmark
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: CLPB
CLPBY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that Coloplast A/S (CLPBY) has limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Unlike exchange-listed companies, OTC Other companies may not be required to meet minimum financial standards or adhere to strict corporate governance guidelines. This tier carries higher risks due to the potential for less transparency and liquidity.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited transparency and regulatory oversight.
- Potential for low trading volume and wide bid-ask spreads.
- Higher risk of fraud or manipulation.
- Uncertainty regarding the availability and reliability of financial information.
- Greater price volatility compared to exchange-listed stocks.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements.
- Assess the company's management team and track record.
- Research the company's industry and competitive landscape.
- Evaluate the company's business model and revenue streams.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Established operating history and market presence.
- Positive customer reviews and testimonials.
- Experienced management team with relevant industry expertise.
- Partnerships with reputable organizations or institutions.
- Compliance with applicable laws and regulations.
CLPBY Healthcare Aktien-FAQ
What are the key factors to evaluate for CLPBY?
Coloplast A/S (CLPBY) currently holds an AI score of 48/100, indicating low score. Key strength: Strong brand recognition and customer loyalty.. Primary risk to monitor: Potential: Increasing competition from generic manufacturers in key product segments.. This is not financial advice.
How frequently does CLPBY data refresh on this page?
CLPBY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CLPBY's recent stock price performance?
Recent price movement in Coloplast A/S (CLPBY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand recognition and customer loyalty.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CLPBY overvalued or undervalued right now?
Determining whether Coloplast A/S (CLPBY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CLPBY?
Before investing in Coloplast A/S (CLPBY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CLPBY to a portfolio?
Potential reasons to consider Coloplast A/S (CLPBY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong brand recognition and customer loyalty.. Additionally: Diversified product portfolio across multiple healthcare segments.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CLPBY?
Yes, most major brokerages offer fractional shares of Coloplast A/S (CLPBY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CLPBY's earnings and financial reports?
Coloplast A/S (CLPBY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CLPBY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data and market projections are based on available information and industry reports.
- Analyst opinions and ratings are subject to change without notice.
- Investment decisions should be based on individual risk tolerance and financial circumstances.